Proximagen Group Limited
Records under this name other than patents Proximagen Group Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Proximagen Group Limited
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,155,761 | CXCR4 Receptor Antagonists Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,428,066 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,530,208 | Imidazo[4,5-c]pyridine Derived Ssao Inhibitors Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 11,369,616 | Drug Combination and Its Use in Therapy Formerly held Lapsed on the fee record Ended Jun 28, 2026 · High confidence | Lapsed on the fee record | Ended Jun 28, 2026 | High confidence |
| US 11,311,552 | Therapies for cancer Formerly held Lapsed on the fee record Ended Apr 26, 2026 · USPTO record | Lapsed on the fee record | Ended Apr 26, 2026 | USPTO record |
| US 9,951,068 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors Formerly held Lapsed on the fee record Ended Apr 24, 2026 · USPTO record | Lapsed on the fee record | Ended Apr 24, 2026 | USPTO record |
| US 9,676,769 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors Formerly held Lapsed on the fee record Ended Jun 13, 2025 · USPTO record | Lapsed on the fee record | Ended Jun 13, 2025 | USPTO record |
| US 9,580,415 | Compounds Formerly held Lapsed on the fee record Ended Feb 28, 2025 · USPTO record | Lapsed on the fee record | Ended Feb 28, 2025 | USPTO record |
| US 9,428,498 | Substituted imidazo[4,5-c]pyridine compounds and compositions thereof Formerly held Lapsed on the fee record Ended Aug 30, 2024 · USPTO record | Lapsed on the fee record | Ended Aug 30, 2024 | USPTO record |
| US 10,738,044 | Therapeutic compound and use in therapy Formerly held Lapsed on the fee record Ended Aug 11, 2024 · USPTO record | Lapsed on the fee record | Ended Aug 11, 2024 | USPTO record |